Sonnet BioTherapeutics Bolsa (NASDAQ: SONN)

Últimas noticias sobre Sonnet BioTherapeutics (NASDAQ:SONN) Bolsa

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) with a Overweight and lowers the price target from $62 to $60.

News

Price Target

Analyst Ratings

TARS

Barclays Maintains Overweight on Tarsus Pharmaceuticals, Lowers Price Target to $60

Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) is looking for FY2025 FFO of $1.01-$1.11 vs $1.12 analyst estimate. sees sales of $298.000 million-$305.000 million vs $328.90 million analyst estimate.

Guidance

CLDT

Chatham Lodging Sees FY2025 FFO $1.01-$1.11 vs $1.12 Est; Sees Sales $298.000M-$305.000M vs $328.90M Est

Business Outlook for 2025
Based on the growth momentum in both YouCam mobile apps and web subscriptions and enterprise SaaS solution demands, the Company anticipates a year-over-year total revenue growth rate of 13% to 14.5% for 2025, compared to 2024.
Note that this forecast is based on the&nbsp;

PERF

Perfect Sees FY2025 Sales $68.030M-$68.930M vs $69.17M Estimate

Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) is looking for Q1 FFO of $0.12-$0.15 vs $0.14 analyst estimate. sees sales of $67.900 million-$68.500 million vs $71.47 million analyst estimate.

Chatham Lodging Sees Q1 FFO $0.12-$0.15 vs $0.14 Est; Sees Sales $67.900M-$68.500M vs $71.47M Est

Advance Auto Parts Sees FY27 Net Sales Of $9.0B; Comparable Store Sales In Positive Low-Single-Digit %

Earnings

DT Midstream Q4 2024 Operating EPS $0.94 Beats $0.89 Estimate

United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.71 by 29.58 percent. This is a 19.35 percent decrease over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $384.38 million which beat the analyst consensus estimate of $380.04 million by 1.14 percent. This is a 1.18 percent decrease over sales of $388.96 million the same period last year.

Earnings Beats

Earnings Misses

PRKS

United Parks & Resorts Q4 EPS $0.50 Misses $0.71 Estimate, Sales $384.38M Beat $380.04M Estimate

Barclays analyst Raimo Lenschow maintains Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) with a Overweight and lowers the price target from $38 to $34.

Barclays Maintains Overweight on Sprout Social, Lowers Price Target to $34

Advance Auto Parts Sees FY25 Comparable Store Sales To Decline About 2%

Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.12 by 25 percent. This is a 31.82 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $347.00 million which missed the analyst consensus estimate of $351.26 million by 1.21 percent. This is a 0.87 percent increase over sales of $344.01 million the same period last year.

ARHS

Arhaus Q4 2024 GAAP EPS $0.15 Beats $0.12 Estimate, Sales $347.00M Miss $351.26M Estimate

WIIM

GM shares are trading higher after the company approved a new share repurchase authorization and increased its dividend.

ITRN

Ituran Location Declared 25% Increase To Dividend Policy To $10M, Or $0.50 Per Share Per Quarter, From $8M In Recent Prior Quarters

Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) sees Q1 sales of $16.300 million-$16.600 million vs $16.10 million analyst estimate.

Valens Semiconductor Sees Q1 Sales $16.300M-$16.600M vs $16.10M Est

Dividends

GM Board Approves Increasing Dividend From $0.12 To $0.15/Share

Barclays analyst Trevor Young maintains Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) with a Equal-Weight and raises the price target from $25 to $26.

RVLV

Barclays Maintains Equal-Weight on Revolve Gr, Raises Price Target to $26

Advance Auto Parts Sees FY25  Sales From Continuing Operations Of About $2.5B

Our 2025 annual guideposts of Core adjusted EBITDA are in the range of $1.00 to $1.05 billion," said Kyle Lorentzen, Chief Financial Officer.

COMM

CommScope Holding Expects FY25 Core Adj EBITDA Of $1.00B-$1.05B

Buybacks

GM Board Approves New $6B Share Repurchase Authorization; Co. Enters Into Accelerated Share Repurchase Program To Execute $2B Of The Repurchase Authorization

CBIZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBZ#NYSE">CBZ</a>) is looking for FY2025 GAAP EPS of $1.97-$2.02 vs $3.02 analyst estimate..

CBIZ Sees FY2025 GAAP EPS $1.97-$2.02 vs $3.02 Est

Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $75.11 million which beat the analyst consensus estimate of $74.65 million by 0.62 percent. This is a 3.92 percent increase over sales of $72.28 million the same period last year.

Chatham Lodging Q4 FFO $0.20 Beats $0.17 Estimate, Sales $75.11M Beat $74.65M Estimate

Press Releases

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Management

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Health Care

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Comments

Sonnet BioTherapeutics

Noticias

Últimas noticias sobre Sonnet BioTherapeutics (NASDAQ:SONN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL